• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of ISG-mediated suppression of mesenchymal tumor stromal cells by miRNAs in human T cell-released exosomes

Research Project

Project/Area Number 18K15275
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionMie University

Principal Investigator

Momose Fumiyasu  三重大学, 医学系研究科, 産学官連携講座助教 (20798326)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsエクソソーム / miRNA / 間葉系幹細胞 / ISG / Type-I IFN / ISGs / IFN / miRNA過剰発現細胞モデル / T細胞エクソソーム / miRNAs / がん間質
Outline of Final Research Achievements

In the development of inhibitors for modulation of mesenchymal tumor stroma, we have identified that the exosomal miR-6089 and miR-6090 released by human T cells have a possibility to suppress mesenchymal stem cell (MSC) activity in an interferon-stimulated gene (ISG)-mediated manner. In this study, we tried to investigate whether miR-6089 and miR-6090 induce ISGs and type I IFN-related genes, and consequently influence on MSC activities by establishing those miRNA-overexpression cell line models. As a result, miR-6089 and miR-6090 were found to enhance ISGs and type I IFN-related genes, such as IFN-β, expressions and influence on the proliferation and differentiation of MSCs. Our finding suggest that those miRNAs play a critical role in MSC activities in an ISG-mediated manner.

Academic Significance and Societal Importance of the Research Achievements

転移を伴うがん患者の生存率は、早期がん患者と比べ著しく低下する。そのため、現在がんの浸潤・転移を標的とした治療薬の早急な開発が社会的に求められている。本研究では、T細胞エクソソームに含まれるmiRNAsがISGsやIFN関連遺伝子を誘導し、がんの浸潤・転移を促進するMSCを抑制することを見出した。この様ながん間質細胞にフォーカスしたExosomal miRNAsの作用は世界的にも稀少で、がん転移機構の解明にとって重要である。本研究成果を踏まえた今後の発展により本機構が解明できれば、従来の抗がん剤とは異なる新規機序のがん浸潤・転移阻害薬を創製し、がん創薬研究が大きく進展する可能性が期待される。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2019 2018

All Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (3 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Exosomal regulation of lymphocyte homing to the gut2018

    • Author(s)
      Park Eun Jeong、Prajuabjinda Onmanee、Soe Zay Yar、Darkwah Samuel、Appiah Michael G.、Kawamoto Eiji、Momose Fumiyasu、Shiku Hiroshi、Shimaoka Motomu
    • Journal Title

      Blood Advances

      Volume: 3 Issue: 1 Pages: 1-11

    • DOI

      10.1182/bloodadvances.2018024877

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Only a portion of the T cell-released exosomes has a capacity to destruct mesenchymal tumor stroma2019

    • Author(s)
      Naohiro Seo, Tsuguhiro Kaneda, Junko Nakamura, Fumiyasu Momose, Kazunari Akiyoshi, Hiroshi Shiku
    • Organizer
      International Society for Extracellular Vesicles 2019
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] Preparation of human T cell-derived exosomes with high purity and quality for clinical use against advanced tumor2019

    • Author(s)
      Naohiro Seo, Junko Nakamura, Fumiyasu Momose, Asako Shimoda, Kazunari Akiyoshi, Tsuguhiro Kaneda, Hiroshi Shiku
    • Organizer
      第78回日本癌学会総会
    • Related Report
      2019 Research-status Report
  • [Presentation] CTLの放出するエクソソームの一部が間葉系細胞で構成されるがん間質傷害に関与する2019

    • Author(s)
      瀬尾 尚宏, 中村 純子, 百瀬 文康, 下田 麻子, 秋吉 一成, 金田 次弘, 珠玖 洋
    • Organizer
      第23回日本がん免疫学会総会
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi